)
)
)
Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company focused genetic cardiomyopathies. Tenaya’s pipeline includes clinical-stage assets including TN-201 (Ph1), a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401 (Ph1), a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), and TN-301 (Ph1), a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease,
Address
South San FranciscoCalifornia
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
)
)
)
)